Health
Virus drug benefit only marginal: study – Tenterfield Star
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly short…
Moderately ill COVID-19 patients had their condition improve after a 5-day course of Gilead Sciences Inc’s remdesivir but the drug did not significantly shorten hospital stays and a 10-day course did not show a benefit, according to new data.
The drug, which was shown in a trial of severely ill COVID-19 patients to shorten their hospital recovery time, has been at the forefront of the battle against the pandemic.
The 600-patient analysis, published on Friday by the Journal of the American Medi…
-
Noosa News18 hours agoHow Lily Steele-Park took her rapist to court and won
-
Business23 hours agoFord CEO makes stunning prediction about artificial intelligence
-
General24 hours agoRush to buy homes before rate cuts send prices soaring
-
Business20 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025